Open-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Age ≥ 18 to ≤ 75 years old.
Able to understand and provide a signed informed consent that fulfils the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
Have completed ≥ 2 lines of cytotoxic chemotherapy.
Have received rituximab or another anti-CD20 antibody.
Histologically documented large B-cell lymphomas (eg, diffuse large B-cell lymphoma [DLBCL], anaplastic large cell lymphoma [ALCL], follicular large cell lymphoma, mantle cell lymphoma), primary central nervous system (CNS) lymphoma, chronic lymphocytic leukemia (CLL), Burkitt and Burkitt-like lymphoma.
Known hypersensitivity or allergy to any component of the study medications, including sulfa containing study medication(s) (eg, albumin [human], dimethyl sulfoxide [DMSO]).
ANC < 1000 cells/mm3.
Platelet count < 100,000 cells/mm3.